Description

The Virtual Grand Rounds Series provides your institution with consistent, high-quality, one-hour educational programs, presented by the Massachusetts General Hospital Psychiatry Academy’s world-renowned faculty. Led by Program Directors Jerrold F. Rosenbaum, MD, Psychiatrist in Chief at Massachusetts General Hospital, and Maurizio Fava, MD, Executive Vice Chair of the Psychiatry Dept. at Massachusetts General Hospital, the Virtual Grand Rounds Series allows doctors, residents, and medical students to conveniently acquire knowledge about clinical challenges and innovative treatment options for a variety of psychiatric disorders. Given the time constraints of today's clinical practice, the online format of the Virtual Grand Rounds Series means your medical staff can participate in real-time or choose to view the archived version whenever time allows. When viewed in live format, interactive features are enabled that let program faculty provide live feedback to questions and communicate directly with you and your staff.

Learning Objectives

Date

Grand Rounds

Learning Objectives

9/7/2011

Adjunctive Therapies in the Treatment of Schizophrenia: For Whom and For What?

Donald C. Goff, MD
  • Recognize the relative evidence for efficacy of common adjunctive agents.
  • Formulate an approach to the treatment resistant patient with schizophrenia.
  • Identify specific adjunctive agents.

9/21/2011

Cognitive-Behavioral Therapy

Susan Sprich, PhD and Timothy J. Petersen, PhD
  • Describe fundamental principles of CBT.
  • Explain strategies for engaging patients in this treatment.
  • Identify ways to conceptualize a common psychiatric disorder using a CBT framework.

10/5/2011

Neurosurgical Treatments for Psychiatric Illness

Darin D. Dougherty, MD
  • Explain the efficacy and safety profile of vagus nerve stimulation for treatment resistant depression.
  • Review the use of transcranial magnetic stimulation for the treatment of depression.
  • Recognize the use of deep brain stimulation for intractable psychiatric illness.

10/19/2011

Treatment Resistant Depression

George Papakostas, MD
  • Describe evidenced based polypharmacy strategies (augmentation and combination) for antidepressant partial- and non-responders with MDD.
  • Identify monotherapy strategies (dose increase and switching) for antidepressant partial- and non-responders with MDD.
  • Describe factors which help guide treatment selection in this population.

11/2/2011

Challenges Remain in the Diagnosis of Pediatric Bipolar Disorder

Janet R. Wozniak, MD
  • Recognize that the diagnosis of pediatric bipolar disorder can be complicated by its developmentally distinct clinical presentation and complicated comorbidity.
  • Review the emerging family genetic and longitudinal course evidence supporting the validity of the diagnosis of pediatric bipolar disorder.
  • Identify the mood stabilizers used in the treatment of pediatric bipolar disorder.

11/16/2011

Treatment of Mood Disorders During Pregnancy: Lessons from Two Decades

Lee S. Cohen, MD
  • Review data on the course of psychiatric disorders during pregnancy and postpartum.
  • Recognize the risks of psychotropic drug use during pregnancy versus risk of untreated maternal psychiatric illness.
  • Identify the relative risk of older versus newer antidepressants when used during pregnancy and the relative risks of psychiatric relapse following discontinuation of agents such as mood stabilizers or antidepressants.

11/30/2011

Acupuncture and Cranial Electrical Stimulation (CES) in Psychiatry

David Mischoulon, MD
  • To understand the current evidence for acupuncture treatment of depression.
  • To understand the current evidence for cranial electrical stimulation for various psychiatric disorders.
  • To understand proposed mechanisms of action for the above treatments.

12/14/2011

The Heavy Burden of Psychiatric Comorbidity Associated with Autism Spectrum Disorders

Gagan Joshi, MD
  • Recognize the significant presence of autism spectrum disorders (ASD) in psychiatrically referred populations
  • Explain the heavy burden of psychiatric comorbidity in individuals with ASD.
  • Identify the neural abnormalities associated with ASD.

Faculty

  • Lee S. Cohen, MD
    Director, Perinatal and Reproductive Psychiatry Program, MGH
    Edmund N. and Carroll M. Carpenter Associate Professor of Psychiatry, Harvard Medical School
  • Darin D. Dougherty, MD
    Director, Division of Neurotherapeutics, Department of Psychiatry, MGH
    Associate Director, Psychiatric Neuroimaging Group, MGH
    Associate Professor of Psychiatry, Harvard Medical School
  • Maurizio Fava, MD
    Executive Vice Chair, Department of Psychiatry, MGH
    Executive Director, Clinical Trials Network & Institute (CTNI), MGH
    Director, Depression Clinical & Research Program, MGH
    Slater Family Professor of Psychiatry, Harvard Medical School
  • John A. Fromson, MD
    Co-Director, MGH Postgraduate Medical Education
    Assistant Clinical Professor of Psychiatry, Harvard Medical School
  • Donald C. Goff, MD
    Director, Schizophrenia Program, MGH
    Medical Director, Freedom Trail Clinic, Erich Lindemann Mental Health Center
    Professor of Psychiatry, Harvard Medical School
  • Gagan Joshi, MD
    Clinical Investigator, Pediatric Psychopharmacology Clinical and Research Programs, MGH
    Instructor in Psychiatry, Harvard Medical School
  • David Mischoulon, MD, PhD
    Director of Research, Depression Clinical and Research Program, MGH
    Associate Professor of Psychiatry, Harvard Medical School
  • George I. Papakostas, MD
    Director of Treatment-Resistant Depression Studies, Department of Psychiatry, MGH
    Associate Professor of Psychiatry, Harvard Medical School
  • Timothy J. Petersen, PhD
    Associate Director, Division of Postgraduate Education, MGH
    Assistant Professor of Psychiatry, Harvard Medical School
  • Jerrold F. Rosenbaum, MD
    Psychiatrist in Chief, Massachusetts General Hospital
    Stanley Cobb Professor of Psychiatry, Harvard Medical School
  • Susan E. Sprich, PhD
    Clinical Director, Cognitive Behavioral Therapy Program, MGH
    Assistant Professor of Psychology in the Department of Psychiatry, Harvard Medical School
  • Janet Wozniak, MD
    Director, Pediatric Bipolar Disorder Clinical and Research Program, MGH
    Assistant Professor of Psychiatry, Harvard Medical School

CME Information

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of McLean Hospital and the Massachusetts General Hospital Psychiatry Academy. McLean Hospital is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation
PHYSICIANS: McLean Hospital designates this continuing medical educational activity for a maximum of 1 AMA PRA Category 1 Credit(TM) per presentation. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PSYCHOLOGISTS: The Massachusetts General Hospital, Department of Psychiatry, is approved by the American Psychological Association to offer Continuing Education (CE) for psychologists and maintains responsibility for this program. This offering meets the criteria for 1 Continuing Education (CE) credit per presentation for psychologists.

NURSES: This program meets the requirements of the Massachusetts Board of Registration in Nursing (224 CMR 5.00) for 1 contact hour of nursing continuing education credit per presentation.

SOCIAL WORKERS: This program has been approved for 1 Social Work Continuing Education hour for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D51021.

Policy on Faculty and Provider Disclosure
It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). McLean Hospital has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.

Accreditation information for nurses, psychologists and social workers forthcoming!

Faculty Disclosures

Lee S. Cohen, MD

Research Support

Astra-Zeneca Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Berlex Laboratories, Eli Lilly & Company, Forest Laboratories Inc., GlaxoSmithKline, Janssen Pharmaceuticals, National Institute of Mental Health, National Institutes of Health, National Alliance for Research on Schizophrenia and Depression, Sepracor Inc., Stanley Medical Research Institute, Good Samaritan Foundation, van Ameringen Foundation Inc., Abbott Pharmaceuticals, Organon Inc., Sanofi-Synthelabo Inc., Pfizer Inc., and Wyeth-Ayerst Pharmaceuticals.

Speaking/Honoraria

Astra-Zeneca Pharmaceuticals, Berlex Pharmaceuticals, Eli Lilly & Company, Forest Laboratories Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Pfizer Inc., and Wyeth-Ayerst Pharmaceuticals.

Advisory/Consulting

Eli Lilly & Company, GlaxoSmithKline, Janssen Pharmaceuticals, JDS/Noven Pharmaceuticals, Novartis Pharmaceuticals, Ortho-McNeil Pharmaceuticals, Pamlab, L.L.C, and Wyeth-Ayerst Pharmaceuticals.

Last updated: 7/27/2010

Darin D. Dougherty, MD

Research Support

Medtronic, Cyberonics, Northstar Neuroscience, Eli Lilly & Co., Forest, McNeil, and Cephalon.

Speaking/Honoraria

Medtronic, Cyberonics, Northstar Neuroscience, and McNeil.

Advisory/Consulting

Jazz Pharmaceuticals, Trancept Pharmaceuticals, and Medtronic.

Last updated: 7/27/2010

Maurizio Fava, MD

Research Support

Abbott Laboratories, Alkermes, Aspect Medical Systems, Astra-Zeneca, Bio Research, BrainCells Inc., Bristol-Myers Squibb, Cephalon, Clinical Trial Solutions, Eli Lilly & Co., Forest Pharmaceuticals Inc., Ganeden, GlaxoSmithKline, J&J Pharmaceuticals, Lichtwer Pharma GmbH,  Lorex Pharmaceuticals, NARSAD, NCCAM, NIDA, NIMH, Novartis, Organon Inc., PamLab LLC, Pfizer Inc, Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay Pharmaceuticals Inc., Synthelabo, and Wyeth-Ayerst Laboratories 

Speaking/Publishing

Advanced Meeting Partners, American Psychiatric Association, Astra-Zeneca, Belvoir, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Eli Lilly & Co., Forest Pharmaceuticals Inc., GlaxoSmithKline, Imedex , Novartis, Organon Inc., Pfizer Inc, PharmaStar, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed-Elsevier, UBC, Wyeth-Ayerst Laboratories

Advisory/Consulting

Abbott Laboratories, Amarin, Aspect Medical Systems , Astra-Zeneca, Auspex Pharmaceuticals, Bayer AG, Best Practice Project Management Inc, Biovail Pharmaceuticals Inc., BrainCells Inc, Bristol-Myers Squibb,  Cephalon, Clinical Trials Solutions, CNS Response, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eli Lilly & Co., EPIX Pharmaceuticals, Fabre-Kramer, Pharmaceuticals Inc., Forest Pharmaceuticals Inc., GlaxoSmithKline, Grunenthal GmBH, Janssen Pharmaceuticals, Jazz Pharmaceuticals, J&J Pharmaceuticals, Knoll Pharmaceuticals, Labopharm , Lorex Pharmaceuticals, Lundbeck , MedAvante Inc. Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab LLC, Pfizer Inc , PharmaStar , Pharmavite , Precision Human Biolaboratory,  Roche, Sanofi-Aventis,  Sepracor, Schering-Plough, Solvay Pharmaceuticals Inc., Somaxon,  Somerset Pharmaceuticals, Synthelabo,  Takeda,  Tetragenex,  Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc,  and Wyeth-Ayerst Laboratories

Equity Holdings

Compellis

Royalty/Patent, Other Income

Patent applications for SPCD and for a combination of azapirones and bupropion in MDD, copyright royalties for the MGH CPFQ, SFI, ATRQ, DESS, and SAFER

Last updated: 7/27/2010

John A. Fromson, MD

Dr. Fromson has indicated that neither he nor any member of his immediate family has a significant financial interest or affiliation with the manufacturer of a commercial product or provider of a commercial service.

 

Last updated: 1/3/2012

 

Donald C. Goff, MD

Research Support

Pfizer, Cephalon, and Janssen.

Speaking/Honoraria

Pfizer, Cephalon, Janssen, Xenoport, Dainippon Sumitomo, Solvay/Wyeth, Bristol-Myer Squibb, Versumed, Letters and Science, SG Cowen, Vista Research, Organon, Proteus, Genactics, Forest, Xytis, MedReviews LLC, and Vanda Pharmaceuticals.

Last updated: 7/27/2010

Gagan Joshi, MD

David Mischoulon, MD, PhD

Research Support

Laxdale (Amarine), Nordic Naturals, and Ganaden.

Speaking/Honoraria

Pamlab LLC.

Advisory/Consulting

Bristol-Myers Squibb.

Royalty/Patent

Back Bay Scientific for PMS Escape.

Last updated: 7/27/2010

George I. Papakostas, MD

Timothy J. Petersen, PhD

Speaking/Honoraria

Bristol-Myers Squibb, Eli Lilly & Co., and Organon, Inc.

Advisory/Consulting

Johnson and Johnson.

Last updated: 7/27/2010

Jerrold F. Rosenbaum, MD

Speaking/Honoraria

Boehringer-Ingelheim, BMS, Cyberonics, Forest, Lilly, Reed Elsevier, and Schwartz.

Advisory/Consulting

Auspex, Astra-Zeneca, Bristol-Myers Squibb, Cephalon, Compellis, Cyberonics, EPIX, Forest, GSK, Janssen, Lilly, MedAvante, Neuronetics, Novartis, Orexigen, Organon, Pfizer, Roche Diagnostics, Sanofi, Shire, Somaxon, Somerset, Sepracor, Supernus, and Wyeth.

Equity Holdings

Compellis, Medavante, Somaxon, and Supernus.

Last updated: 7/27/2010

Susan E. Sprich, PhD

No disclosures indicated.

Last updated: 7/27/2010

Janet Wozniak, MD

Location

online